US life sciences consulting firm and incubator invests in Cortical Dynamics Ltd
BPH Energy Limited (ASX:BPH) has announced that investee Cortical Dynamics has secured a $250,000 investment from IntuitiveX and Korean based VC investor, Gentium Partners.
Cortical is an Australian based medical device technology company that developed a next generation Brain Function Monitor and is now commercialising the intellectual property.
Its core product, the Brain Anaesthesia Response (BARM) System, was developed to better detect the effect of anaesthetic agents on brain activity.
IntuitiveX (www.intuitive-x.com) is a Seattle-based life science consulting firm and incubator that brings to Cortical extensive experience in the US capital raising and commercialisation arena and will assist Cortical in the FDA regulatory approval process.
The IntuitiveX management team is comprised of life science entrepreneurs, physicians, investors, and innovators and brings a combined 100+ years of experience in R&D, clinical, IP strategy, prototyping, product development, and commercialisation. It has investments in eleven MedTech, digital health, robotics to augmented reality, and 3-D printing to biotech.
Korean asset management company, Gentium Partners (GP) assists venture companies, particularly those in the startup stages, with mentoring and fund raising. GP prefers to invest in companies with innovative technologies and/or ideas, particularly when they are impactful in healthcare, environment, and lifestyle.
Mr Charles Chang and Mr Ashley Zimpel will join the Cortical board following the resignations of other Cortical directors, while BPH director David Breeze remains as a Cortical board member.
Cortical Dynamics is working with BPH Energy, which currently holds 4.38% of Cortical Dynamics, and Swinburne University of Technology to develop and commercialise a unique depth of anaesthesia monitoring system for use during major surgery.
Cortical’s BARM System is applied via an adhesive sensor to the forehead, to measure a patient’s brain electrical activity, the electroencephalogram (EEG), in order to indicate how deeply anaesthetised a patient is during an operation. This aids anaesthetists in keeping patients optimally anaesthetised, ensuring patients do not wake unexpectedly, and it reduces the incidence of side effects associated with the anaesthetic.
In addition to Cortical Dynamics, BPH has an investment in the medicinal cannabis space via Patagonia Genetics Pty Ltd. BPH Energy’s major investment is in Advent Energy Ltd, an unlisted oil and gas exploration and development company with onshore and offshore exploration and near-term development assets around Australia.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.